A Phase Ib/II Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Docetaxel; Doxorubicin; Gemcitabine; Irinotecan; Paclitaxel; Vinorelbine
- Indications Adenocarcinoma; Breast cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Acronyms PembroPlus
- 08 Aug 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2018.
- 08 Aug 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2018.
- 08 Aug 2017 Status changed from recruiting to active, no longer recruiting.